secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0000950170-22-016870
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC reports Q2 2022 cash $237.8M; three Phase 1 readouts expected 1H 2023
--------------------------------------------------------------------------

- Cash and investments $237.8M as of June 30, 2022; funds operations into 2H 2024.
- R&D expenses $13.8M for Q2 2022, down from $15.5M in Q2 2021, mainly on lower ORIC-101 costs.
- G&A expenses $6.9M for Q2 2022, up from $5.5M in Q2 2021, due to higher personnel costs.
- Three ongoing Phase 1 programs (ORIC-533, ORIC-114, ORIC-944) with initial data expected 1H 2023.
- Preclinical data on PLK4 inhibitor program presented at AACR in April 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000095017022016870/0000950170-22-016870-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000095017022016870/oric-20220811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016870

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer